Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02743078
Title Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors RTOG Foundation, Inc.
Indications

gliosarcoma

giant cell glioblastoma

glioblastoma

high grade glioma

Therapies

Bevacizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.